Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study

Abstract

ObjectiveTo evaluate the efficacy and safety of low-dose (45 mg) intravesical bacille Calmette–Guérin (BCG) therapy in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC), as intravesical BCG is the most acceptable adjuvant therapy for NMI transitional cell carcinoma of the bladder. However, in the standard regimen, undesirable effects are the main cause of treatment discontinuation.Patients and methodsThe present study included 37 men with primary NIMBC. All patients underwent complete TURB and 2 weeks later, a 6-week course of 45 mg BCG diluted in 50 mL isotonic saline was instilled into the bladder and retained for 2 h. Patients were evaluated for BCG efficacy (recurrence with or without progression) and safety by documentation of minor and/or major side-effects.ResultsThere were no major or severe side-effects and no treatment discontinuations. Local adverse effects occurred in 20 patients, while systemic effects, in the form of fever, occurred in six patients (16.2%). There was recurrence in 14 patients (37.8%) after 18–34 months, with disease progression (muscle invasion) in four (10.8%) after 6–18 months. The recurrence index was 0.39/100 patients/month and the mean (range) tumour-free period was 30.97 (7–36) months.ConclusionLow-dose BCG intravesical therapy is an effective adjuvant treatment in NMIBC. However, this needs to be validated in future studies and in comparison with other proposed doses and/or regimens.

Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa

“…Both abstracts and full text were reviewed for epidemiology, risk factors, clinical presentation (Table 1, [7, 8, 12, 13, 15, 16-23]), cystoscopic diagnosis, urine markers and cytology as well as TURBT, histological types (Table 2, [7, 8, 12, 13, 15, 16-23]), intravesical adjuvant therapy and follow-up. A qualitative evaluation was performed on the various above parameters and a comparative analysis was made between the available African literature with reference to the current guidelines on bladder cancer by the European Urological Association (EAU), American Urological Association (AUA), Society of Urological Oncology (SUO), and the Canadian Urological Association.…”

Иммунотерапия Рака Мочевого Пузыря. Вакцина БЦЖ: Принципы Действия, Эффективность И Безопасность

“…Íå îáíàðóaeåíû ÏÝ, êîòîðûå òðåáîâàëè ïðåêðàùåíèÿ ïðèìåíåíèÿ âàêöèíû. Ëèõîðàäêó îòìå÷àëè â 16,2 % ñëó÷àåâ, ðåöèäèâ îïóõîëè âûÿâëÿëè ó 37,8 % ÷åðåç 12 -34 ìåñ, èíâàçèþ îïóõîëè â ìûøå÷íûé ñëîé ÌÏ -ó 10,8 % ÷åðåç 6 -18 ìåñ ïîñëå çàâåðøåíèÿ íàçíà÷åíèÿ âàêöèíû [67].  ïðîñïåêòèâíîì, ðàíäîìèçèðîâàííîì, ìóëüòèöåíòðîâîì ÊÈ, âûïîëíåííîì íà 138 ïàöèåíòàõ ñ ÍÌÈÔ ÌÏ ñðåäíåé è âûñîêîé ñòåïåíè ðèñêà, îöåíèâàëè ýôôåêòèâíîñòü âàêöèíû.…”

Comparison of the treatment outcome in patients undergoing TUR to patients treated with BCG immunotherapy after TUR: Preliminary results

“…Iako je recidiv čest, pogotvu kod višestrukih tumora, progresija je retka. Glavni prediktor progresije je gradus, a ne stadijum 4 . Stadijum T1 tumora nastaje iz urotela, ali probija bazalnu membranu koja odvaja urotel od dubljih slojeva i ulazi u laminu propriju, ali ne zahvata mišićni sloj.…”

“…Karcinom mokraćne bešike javlja se češće kod osoba muškog pola 4 . U našoj studiji u obe ispitivane grube bilo je više osoba muškog pola.…”